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Abstract 
 Proteins are fundamental building blocks of life in an organism, and to function properly, 
they must adopt an appropriate three-dimensional conformation or conformational ensemble. In 
protein aggregation diseases, proteins misfold to incorrect structures that allow them to join 
together and form aggregates. A wide variety of proteins are involved in these aggregation 
diseases and there are multiple theories of their disease mechanism. However, a common theme 
is that they aggregate into filamentous structures. Therapies that target the process by which the 
aggregating proteins assemble into these similar fibril-like structures may by effective at 
countering aggregation diseases. This requires models that can accurately describe the assembly 
process of the fibrils. An analytical theory was recently described where fibrils grow by the 
templating of peptides onto an existing amyloid core and the kinetics of the templating process is 
modeled as a random walk in the backbone hydrogen bonding space. In this thesis, I present my 
work integrating molecular simulation with this analytical model to investigate the dependence 
of fibril growth kinetics on peptide sequence and other molecular details. Using the Aβ16-22 
peptide as a model system, we first calculate the rate matrix of transitions among all possible 
hydrogen bonding microscopic states using numerous short-time simulations. These rates were 
then used to construct a kinetic Monte Carlo model for simulations of long-timescale fibril 
growth. The results demonstrate the feasibility of using such a theory/simulation framework for 
bridging the significant gap between fibril growth and simulation timescales. At the same time, 
the study also reveals some limits of describing the fibril growth as a templating process in the 
backbone hydrogen bonding space alone. In particular, we found that dynamics in 
nonspecifically bound states must also be considered. Possible solutions to this deficiency are 
discussed at the end. 
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Chapter 1 - Introduction 
 1.1 Protein Aggregation Diseases 
 1.1.1 Introduction 
Proteins are an essential and diverse group of molecules in an organism with many 
different purposes, and the proper functioning of these molecules is essential for life. The three-
dimensional conformational properties of a protein define its activity and are encoded by the 
sequence of its amino acids. Occasionally, proteins may misfold to improper structures, and 
misfolded proteins may further aggregate into large fibrils.1-3 Intracellular and extracellular 
fibrillar aggregates in tissues are a characteristic feature of many protein misfolding diseases, 
which include the most common types of neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s diseases.1-3 The historical term amyloid is typically used to describe the extracellular 
deposits, however it occasionally refers to intra-cellular deposits as well.  
 1.1.2 Pathogenesis 
Although aggregates appear in many protein conformational diseases, it is unclear 
whether they are the source of the disease themselves. The confusion stems from the fact that 
aggregates can be found in clinically healthy people and that there is limited correlation between 
the amount of aggregate deposits and the severity of disease symptoms.4-6 Recent investigation 
suggests that the deposits are a mere side effect of aggregation disorders and that the actual cause 
of disease is the misfolding of proteins.7 The evidence for this idea is inherited cases of 
aggregation diseases whose fibrillar proteins have an inherently higher degree of mutation,8-12 
which may destabilize the protein and cause it to misfold. Moreover, when human pathogenic, 
fibrillar proteins are expressed in animal models, disease symptoms are observed,13-18 although 
there may be no detection of aggregates in some animals.19, 20 These observations support the 
possibility that small aggregates or oligomers of misfolded proteins may be the driving force 
behind protein misfolding diseases. 
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 1.1.3 Features of Amyloidogenic Proteins 
Misfolded protein aggregates share similar structural features21-23 even though the native 
conformation of their constituents may vary widely. Most aggregates in protein conformation 
disorders have a high amount of β-sheet secondary structure with the strands aligned 
perpendicular to the long axis of the fibril.22, 24 To attain the β-sheet structure, there may be 
substantial conformational changes required of the native protein. From what is known, it is 
probable that the native protein experiences a slight change to its conformation, which exposes 
hydrophobic elements that are unstable in an aqueous environment.2, 3 If two or more such 
proteins encounter one another, their hydrophobic parts may associate and form the β-sheet 
structures typical of an amyloid fibril. 
The amyloidogenic Aβ peptide of Alzheimer’s disease is one of the best-characterized 
proteins among those involved in the different aggregation diseases,25 and the amyloid fibrils it 
forms in vitro are equivalent in a variety of experimental tests to plaques removed from 
Alzheimer’s disease tissue.26-29 A hydrophobic fragment of the Aβ peptide containing amino acid 
residues 17 through 21 has been to shown to be an important contributor to the initial phase of 
misfolding and oligomerization.27, 29, 30 Moreover, the addition of hydrophobic amino acids to the 
C-terminus of the Aβ peptide has been shown to increase aggregation.28 These two observations 
support the notion that amyloid formation is partially driven by hydrophobic interactions.  
Polyglutamine-containing segments in proteins may also be a driving force towards 
amyloid formation.31 As has been seen of the amyloidogenic protein in Huntington’s disease, the 
tendency for the peptide to aggregate may be subject to the length of the polyglutamine repeat.32 
The polar amide group of the amino acid glutamine has both a hydrogen bond donor and 
acceptor and the capability to form hydrogen bonds. It is possible, therefore, that glutamine-rich 
peptides tend to aggregate because the side chain amide groups are forming a network of 
hydrogen bonds with each other, which has an overall stabilizing effect on the fibril that forms.33 
Thus, two different and somewhat opposite types of interactions can drive the formation of 
amyloid fibrils: the association of hydrophobic segments on peptides or the interconnection of 
polar hydrogen bonds among amino acid side chains.  
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 1.1.4 Mechanisms of Misfolding and Aggregation 
The occurrence of aggregation diseases is sporadic and one’s susceptibility can be linked 
to both environmental and genetic causes. Genetic makeup that consists of many mutations in a 
gene encoding an amyloidogenic protein is associated with an increased chance of having a 
protein misfolding disease. The mutations destabilize the protein, which allows it to misfold 
more easily and then aggregate. There are several environmental factors that are thought to 
contribute to the misfolding of proteins,3, 25 many of which are prevalent in old age, a 
circumstance supported by the typically late onset of aggregation diseases.34 
The formation of large aggregates has been kinetically shown to follow an initial, slow 
nucleation event in which unfavorable interactions among amyloid molecules lead to an 
oligomeric structure that then undergoes rapid growth to long fibrils.28, 35, 36 Adding pre-formed 
nuclei eliminates the slow nucleation phase. At least two intermediates are recognized in the 
build up to a fully developed amyloid fibril (Figure 1). The first is a soluble oligomer with 
transient, undefined structure composed of about two to ten monomers.37-40 The second 
intermediate is a flexible, short rod-like structure less than 100 nm in length. These so-called 
protofibrils are in equilibrium with the oligomer intermediates,41 and they can form by the 
coalescence of smaller protofibrils at a rate dependent on monomer concentration as well as 
solution properties like temperature, pH, and ionic strength.42 Protofibrils have a high degree of 
β-sheet structure, which facilitates their development to the subsequent fibril state.41 The 
intermediate structures, monomeric proteins, and amyloid fibrils all exist in dynamic 
equilibrium.25, 39 
4 
 
 
Figure 1 A Model of Protein Misfolding and Aggregation. The native protein assumes a 
random coil conformation with exposed hydrophobic elements. The misfolded intermediates are 
stabilized when they aggregate together in an oligomeric structure. Further monomers add to the 
complex to create protofibrils and then fibrils. 
 
 1.1.5 Therapy Considerations 
In neurodegenerative aggregation diseases, the characteristic signs of neuronal death, 
synaptic modifications, and inflammation occur in widely varying parts of the brain, which 
affects what symptoms manifest for the disease.43 Despite the disparity in affected locations 
among the diseases, protein misfolding and aggregation are key events in each disorder. 
Therefore, a potential, comprehensive therapy should target the causal protein misfolding events 
in the initiation of these diseases. A theoretical model that can accurately characterize amyloid 
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growth in accordance with experimental data would be a powerful tool in developing therapies. 
The research presented in this thesis aims to devise such a model. 
 
 1.2 Molecular Dynamics 
 1.2.1 Introduction 
Molecular dynamics (MD) is an important theoretical tool for a wide range of 
applications, including the study of amyloid molecules. MD simulations are generally based on 
molecular mechanics (MM) models, which use empirical potential-energy functions to describe 
the interactions in a molecular system. Atoms are usually represented as spheres and bonds as 
springs. Hooke’s Law can then describe bonded interactions. Nonbonded interactions may be 
described with a Leonard-Jones potential, while Coulomb’s Law describes the interaction among 
charged atoms. The classical equations of motion can be applied to such a system and are solved 
numerically to calculate its trajectory.44  
The trajectories produced by MD simulations can be used to extract information of 
conformational changes on time and spatial scales that are otherwise inaccessible experimentally. 
Computational experiment also allows the manipulation of the system in nonphysical ways to 
obtain insights on certain aspects of the system.45 An example is switching the energy function 
describing one system to that of another during a simulation, which is an important method for 
free-energy calculations.46 
 1.2.2 Protein Dynamics 
Proteins undergo a wide array of dynamic processes with time scales that range from 
femtoseconds to hours. These processes also have a range of physical and energy scales, and 
many are important for the proteins’ biochemical function.47 Fast and microscopic motions are 
typically prominent in enzymatic reactions, while large and slow motions on the scale of entire 
proteins are seen in allosteric coupling and folding transitions. Protein association takes place on 
even larger time and distance scales.  
A primary purpose of MD simulation is to study time-dependent features of proteins and 
other molecules in general to better understand their molecular structure and function. However, 
the atomic position, velocity, and energy data of a simulation trajectory alone provides limited 
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useful information. To obtain the desired macroscopic information of the system, statistical 
mechanics is used to connect microscopic statistics and macroscopic properties, particularly 
thermodynamic quantities. Determination of these macroscopic properties from the microscopic 
MD data can then facilitate the study of a variety of molecular structure, kinetic, and 
thermodynamic aspects. A greater level of exploration of the sampling space by a system 
corresponds to a more thorough navigation of the free energy landscape and consequently more 
accurate macroscopic observables to be calculated. 
 
 1.2.3 Force Fields 
The interparticle interactions within the classical mechanical framework are referred to as 
a force field, which is required as an input to the MD simulator. The force field provides 
parameters for all of the possible interactions present in the system and the accuracy of its 
representation may vary depending on the given parameters and system. The set of parameters in 
a force field is typically determined from experimental or quantum mechanical assessment of 
small molecules, and the resulting values are assumed to be valid for larger molecules. The low 
computational demands of a force field with explicit parameters to describe all interactions make 
it possible to perform the sizable calculations required to simulate large systems such as proteins, 
membranes, and other biological structures. The drawback of explicit force fields is that they 
cannot simulate the breaking or formation of bonds. 
 1.2.4 Implicit Solvation 
For systems consisting of a solute in a bulk solution, the computational cost of 
calculating the interactions between many explicit solvent molecules can be prohibitive in 
simulating long time-scales or observing large conformational transitions.48 Most of the 
computation is spent on calculating the trajectory of the solvent molecules even though the solute 
is the focus of study. So-called implicit solvation can reduce the computational load by capturing 
the solvent effects with the energy function through a potential of mean force term. Explicit and 
implicit solvents both have their strengths and weaknesses; explicit solvents can more accurately 
describe detailed water-protein interaction, while implicit solvents provide a good balance 
between accuracy and efficiency for simulating larger systems and longer timescales. One 
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method of modeling the solvent implicitly assumes that the mean solvation term is proportional 
to the solvent accessible surface area (SASA) of the solute and is discussed more in-depth later.49 
 1.2.5 MD Simulation of Amyloidogenic Proteins 
MD has extensively been used to study processes related to protein aggregation. For 
example, coarse-grained simulations of polyalanine peptides in implicit solvent showed that they 
spontaneously formed fibrils above a concentration-dependent critical temperature above the 
peptide’s folding temperature, which is consistent with experiment results.50 In the study, 
amorphous structures formed initially before an ordered nucleus developed onto which incoming 
peptides formed β strands on either end of the growing fibril.50 The fibril structure from 
simulation was found to be similar to that observed experimentally.50 Yeast prion proteins were 
found to aggregate in in-register, parallel β strands through MD simulation, consistent with x-ray 
diffraction data.51 A mutated sequence of the protein that did not aggregate in an experimental 
study was correspondingly observed not to oligomerize in simulation as well.51 
There have already been many studies that used traditional MD simulations to investigate 
the Aβ peptide. MD simulation of the Aβ16-22 peptide fragment introduced as the model system  
later in this thesis found that the peptide followed an assembly mechanism in which it passed 
from a random coil to an alpha helix to a beta strand in its path to fibril incorporation, a result 
that agrees with experimental studies of longer constructs of the same Aβ peptide.52 In another 
study, different constructs of the Aβ peptide were simulated in explicit water to determine the 
relative stabilities of variously arranged β-sheet clusters.53 The simulations showed that the Aβ16-
22 construct was most stable in an anti-parallel conformation, a finding in agreement with 
experimental studies.54-57 The dock-lock mechanism, proposed by Thirumalai and coworkers, 
suggests a two-step process by which an amyloidogenic peptide assembles onto a fibril.58 The 
first dock step occurs when the disordered monomer encounters the aggregate complex and 
rapidly experiences a dramatic increase in its β-strand content from an initial low value.58 In the 
second lock step, the β-strand content continues to rise at a much slower rate until the peptide 
eventually assumes its optimal structure.58 The analysis for this study was taken from simulations 
of confined volumes of explicit water in which randomly oriented, disordered Aβ16-22 peptides 
were allowed to aggregate into antiparallel β-sheet structures.58 
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Although MD simulations are useful in studying microscopic, short-term behavior of 
amyloid systems, the current simulation time scale limit of approximately 1 millisecond is 
significantly smaller than the times at which large aggregate structures form, with symptoms of 
protein aggregation disease patients developing over the course of years. Hence, short time-scale 
MD cannot be used to directly study the prolonged growth of amyloid fibrils with today’s 
computational capabilities. In response, this thesis presents an approach of combining MD 
simulations of an amyloid system with a simplified theory of amyloid fibril growth to predict 
long-term fibril formation kinetics and mechanism.  
 
Chapter 2 - Integrating Theory and Computation to Study Amyloid 
Kinetics 
 2.1 Kinetic Theory of Amyloid Fibril Templating 
Schmit recently proposed that the ordered β-sheet structure of a growing amyloid fibril, 
typically with in-register and parallel strands as observed from experimentally determined 
structures, could be described by the competition between amino acid sidechain specificity and 
backbone hydrogen bond periodicity.59 Only the addition of monomeric proteins to a fibril (as 
opposed to the coalescence of oligomers) is considered in the theory since low physiologic 
protein concentrations make the former process far more likely; furthermore, the addition of 
single peptides to a fibril is simpler to model. Mis-registered or anti-parallel peptides would have 
a less favorable energy compared to the optimal conformation and would slow the formation of 
the highly ordered fibril structure. The time that a peptide is bound to the amyloid core can be 
described by a random walk of breaking and forming backbone hydrogen bonds. The theory 
predicts that the timescale of peptide release from the end of the fibril, regardless of optimal or 
sub-optimal conformation, is much greater than the time it takes for a peptide to fully bind or 
immediately break from the end of fibril given at least one contact. As such, the growth rate of 
the fibril can be approximated as 
 
where P+ is the probability that an incoming, correctly aligned peptide becomes incorporated 
into the fibril in its optimal conformation, twait is the time that passes before an incorrectly bound 
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peptide releases, and tdiff is the diffusion time of the peptide. When compared to experimental 
results, this calculated growth rate is able to qualitatively capture the effects of concentration, 
temperature, and denaturants on fibril formation. A key limitation of this theory is that it cannot 
predict the sequence dependence of fibril growth, which requires information about the 
microscopic formation and breakage rates of backbone hydrogen bonds of specific residue types. 
These microscopic rates can be readily calculated from MD simulations. The purpose of the 
work presented in this thesis is to investigate if this theoretical framework can be combined with 
molecular simulations to predict and rationalize the dependence of amyloid fibril growth on 
amino acid sequence and other molecular details. 
 2.2 Computational Strategy  
 2.2.1 Overview 
Inspired by the kinetic theory, our overall strategy consists of two main steps. In the first 
step, all possible hydrogen bonding registry states were enumerated and many short (~50 ns) MD 
simulations were performed, from which the mean first passage time of all possible 
conformational transitions was derived. In the second step, a Markov state model was employed 
to perform kinetic Monte Carlo simulations in determining the fibril growth kinetics.  
 
Figure 2 Computational Strategy Flowchart 
 
 2.2.2 Multi-Scale MD Simulations 
In order to achieve adequate sampling of the many possible conformational transitions 
expected of a peptide on the end of an amyloid fibril, many short time-scale simulations were 
performed of a model system consisting of a small amyloid core with two incoming peptides on 
either side. Both incoming peptides were examined in subsequent analysis to effectively double 
10 
 
the sampling measured. In order to minimize computational time, the smallest stable system of a 
bilayer was used as the amyloid core onto which the two incoming peptides joined.  
An incoming strand may form a β-strand on this bilayer in a number of conformations: 
in-register, mis-registered, parallel, or anti-parallel. Two end peptides on either side of the 
bilayer and on opposing sheets were manipulated to imitate an incoming strand joining to the 
amyloid core in all of these possible β-sheet conformations, or configurations as I have chosen to 
term each specific alignment that was simulated. Only anti-parallel β-strand configurations were 
considered since the model peptide (to be described in the next chapter) was observed to form 
anti-parallel fibrils in the experimental study,60 so these configurations would be the most 
physiologically relevant. Also, it was reasoned that parallel β-sheet configurations would 
experience similar conformational transitions that could be understood and estimated by the data 
from anti-parallel simulations. In addition, only mis-registered configurations that had at least 
two backbone hydrogen bond pairs were considered to be simulated since any configuration with 
less than two pairs was assumed to be a transient conformation in the course of fibril growth and 
does not contribute significantly to twait. 
To generate conformations with a particular configuration, a peptide on the end of one of 
the core β-sheets is first translated and rotated so that it makes the backbone hydrogen bond 
contacts appropriate for that configuration. Then, restraints are added to backbone atoms of the 
core peptides and only the backbone atoms on the incoming peptide that are involved in its first 
contact to form with the core. Finally, the system is heated to 1000K; the restraints retain the 
existing core structure, however, the unrestrained portion of the end peptides not involved in the 
first contact undergo rapid fluctuation and become disordered. The resulting structure represents 
the case where it appears two disordered peptides in solution have just made their first contact 
with the amyloid core in the desired backbone hydrogen bond registry. This procedure is 
repeated to generate multiple initial structures of all the configurations to be simulated. See 
Appendix A for representative structures for each configuration. At this point, these bilayer 
structures are simulated for a period of time suitable to observe many transitions that occur 
between the incoming peptides and the core. 
11 
 
 2.2.3 Transition Data Collection 
After the simulations have completed, the trajectories are analyzed to detect and collect 
all conformational transitions sampled by the end peptides. A transition is denoted by any 
formation or breakage of a pair of backbone hydrogen bonds between residues of the end and 
core peptides. The pair of backbone hydrogen bonds of an amino acid is monitored for 
transitions as opposed to a single hydrogen bond since the formation or breakage of the second 
bond in the pair after formation or breakage of the first is likely to be a cooperative and rapid 
event. Therefore, the hydrogen bond pair is determined to have a certain overall “on” or “off” 
state only when both bonds of the pair are formed or broken, respectively. Once the hydrogen 
bond pair enters a given state, the formation or breakage of a single bond in the pair will not 
signal a new state; only when both bonds form or break will the corresponding new state be 
assumed. The distance between the acceptor and donor of the hydrogen bond determines whether 
the bond is formed or broken, and the distance criterion for each is different. The “on” state 
occurs when the distance of both bonds in the pair is shorter than 2.5 angstroms, while the “off” 
state occurs when the distance of both bonds is greater than 3.5 angstroms. The purpose of using 
different bond distance criteria for each state is to remove the possibility of spurious bond 
formation or breakage events that would occur if bonds distances were hovering around a single 
distance cutoff value for both states. 
Whenever a transition occurs, it is recorded in terms of the initial and final free chain 
length (FCL), the residues that are interacting between the end and core peptides at the position 
of transitional hydrogen bond pair, and the time that elapsed since the last transition. The FCL is 
defined as the number of dissociated, disordered amino acids of the end peptide starting from last 
or first residue and counting inwards on the peptide until the first residue bound to the amyloid 
core with backbone hydrogen bonds is encountered. FCL was chosen as a parameter in recording 
transitions because it was reasoned that the viscous drag of the disordered chain is a key factor 
that modulates the hydrogen bond kinetics besides the identities of contacting residues. 
The position of residues whose identity is recorded in a transition depends on whether the 
transition is due to the forming or breaking of backbone hydrogen bonds. For transitions in 
which bonds break, the interacting residues of the end and core peptides are recorded at the 
position of the existing backbone hydrogen bonds that undergo breaking. For transitions of bond 
formation, the residues are recorded at the position where the backbone hydrogen bonds form. In 
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each case, the nature of the residues are noted at positions where the backbone hydrogen bonds 
undergo change since it is reasoned those residues will be the most important influence on bond 
formation or breakage in terms of sidechain interaction. 
 2.2.4 Markov State Model 
Next, a Markov state model (MSM) is employed to simulate the long timescale growth of 
amyloid fibrils. A Markov model simulates a stochastic process in which the fate and dynamics 
of the current state do not depend on its past. The states of MSM include all the possible 
combinations of FCL and residue pairs found in the transition rate matrix.  After the transitions 
are recorded from all trajectories, the average time for each type of transition is determined and 
used to calculate the rate at which a particular state occurs. The Gillespie algorithm creates a 
trajectory of the stochastic system as follows.61 Two random numbers, R1 and R2, are generated 
that determine what state will occur and the amount of time that elapses to reach that state. Given 
the rates k1, k2, … , kn for the possible transitions from the current state and the sum of these 
rates, ktot, state i+1 is the next state to occur in the trajectory such that 
 
is satisfied. The second random number is set equal to the cumulative distribution function 
 
to determine the time that elapses before the state i+1 occurs. Given that the probability function 
follows a single exponential distribution, the resulting explicit formula for this time is 
 
The chosen state and calculated time are appended to the trajectory, at which point the new set of 
accessible states are determined, two new random numbers are generated, and the algorithm 
repeats itself. The model can be initiated from any state and terminated in response to arriving at 
another given state to facilitate the study of any fibril growth process of interest. 
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Chapter 3 - Validating Model Against Experimental Data 
 3.1 Amyloid-β Fragment Test System 
 3.1.1 Introduction 
The test system used to investigate the multi-scale computational strategy is a fragment 
of the Aβ protein (Aβ16-22) for which kinetic data of its self-assembly is available from the 
experimental work performed by the Nilsson group.60 At neutral pH, Aβ16-22 is capable of 
forming amyloid fibrils with anti-parallel β-sheet structure.54-57 The fragment contains 
hydrophobic core residues 16-22 and has the sequence Ac-KLVFFAE-NH2. This segment of the 
protein has a Phe-Phe motif that was the subject of investigation by the experimental study due 
to possibility of its aromatic interactions contributing the chief stabilizing effect on the self-
assembling structures. The authors created mutants with pentafluorophenylalanine (F5-Phe), 
nonaromatic cyclohexane (Cha), Tyr, or Ala incorporated at one or both of the Phe positions, 19 
and 20, in order to examine the importance of the aromaticity of the core, hydrophobic residues. 
The F5-Phe, Cha, and Tyr amino acids offer differing levels hydrophobicity and aromatic 
character than Phe but still maintain the carbon skeleton of the side chain. The F5-Phe and Cha 
residues are more hydrophobic than Phe, while Tyr and Ala are less hydrophobic. The Cha and 
Ala residues are nonaromatic, whereas F5-Phe and Tyr have similar aromatic interactions to Phe. 
The non-natural amino acids Cha and F5-Phe are useful in studying aromatic and hydrophobic 
properties since their carbon skeleton is not changed from the aromatic, natural amino acids, Phe 
and Tyr. 
 3.1.2 Growth Rates Differences Among Amyloid-β Variants 
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Solutions of disaggregated, wildtype Aβ16-
22 and various mutants were monitored to 
characterize their amyloid fibril growth rates. The 
initial concentration of each solution was 55 µM. 
Concentrations of the monomeric species in 
solution for each peptide were measured at 
intervals to provide an approximate evaluation of 
the relative self-assembly kinetics. The 
monomeric concentrations were observed to 
decrease over time, indicating that aggregates 
were forming (Figure 3). Eventually, a dynamic 
equilibrium was reached when the monomer 
levels stabilized at a final critical concentration 
(Cr). The association constant for the binding of a 
single monomer to the aggregate is then computed 
as 
 
The wildtype sequence exhibited a lag phase of 12 
hours before self-assembly began, which then 
continued for about 14 days before a state of 
dynamic equilibrium was reached. The sequences 
with less hydrophobic residues Ala and Tyr 
substituted at position 19 did not display any 
growth given the initial concentration of 55 µM. 
Another trial of the less hydrophobic sequences 
with a higher initial concentration of 100 µM still 
did not experience any self-assembly of peptides. 
The sequences with Cha or F5-Phe substituted at 
position 19, position 20, or positions 19 and 20 all 
experienced a significant increase in the rate of 
Figure 3 Sedimentation Data for 
Fibrillization of Wildtype and Mutant 
Aβ16-22 Peptides. The sedimentation data 
reveals that monomer peptide concentration 
for Aβ16-22 variants decreases over time, 
indicating fibrillization. (A) Short-term, 6 
hour time range for all variants. (B) Long-
term, 21 day time range for wildtype, Phe19 
à Ala, and Phe19 à Tyr variants. Figure 
adapted from the Nilsson group 
experimental paper.54 
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fibril growth, with dynamic equilibrium being reached within 30 minutes for each case. In 
addition, the variant critical concentrations differed from that of the wildtype sequence. The 
experimental sequences and corresponding critical concentrations are listed in Table 1. This data 
provides an opportunity to substantiate the theoretical model if the model is capable of capturing 
the differences in self-assembly rates and critical concentrations between the wildtype and 
variant sequences. The kinetic data of the wildtype peptide and the cyclohexane mutant peptides 
Cha 19, Cha 20, and Cha 19,20 will be the primary benchmark since MD force field parameters 
are available for these sequences. 
 
Table 1 Aβ16-22 Variants and Critical Concentrations for Self-assembly 
Peptide Sequence Variant CR/µM 
1 Ac-KLVFFAE-NH2 Native (Phe) 33 ± 3 
2 Ac-KLVAFAE-NH2 Phe19 à Ala > 100 
3 Ac-KLVYFAE-NH2 Phe19 à Tyr > 100 
4 Ac-KLV(F5-Phe)FAE-NH2 Phe19 à F5-Phe 4 ± 1 
5 Ac-KLV(Cha)FAE-NH2 Phe19 à Cha 44 ± 3 
6 Ac-KLVF(F5-Phe)AE-NH2 Phe20 à F5-Phe 7 ± 1 
7 Ac-KLVF(Cha)AE-NH2 Phe20 à Cha 22 ± 1 
8 Ac-KLV(F5-Phe)(F5-Phe)AE-NH2 Phe19,20 à F5-Phe 1 ± 1 
9 Ac-KLV(Cha)(Cha)AE-NH2 Phe19,20 à Cha 32 ± 2 
  Data from the Nilsson group experimental paper.60 
 3.2 MD Simulation Details 
Solvent accessible surface area (SASA) implicit solvent was used to greatly increase the 
achievable simulation times of the amyloid test system and thus the number of conformational 
transitions to be observed compared to an explicit solvent system. The total Hamiltonian of an 
explicit solvent system can be summed into solute-solute, solute-solvent, and solvent-solvent 
terms: 
 
To convert to implicit solvent from explicit solvent, the Hamiltonian is integrated over the 
solvent coordinates to obtain the potential of mean force or effective energy, W(r),  
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for a solute having M atoms with Cartesian coordinates r = (r1,…,rM). The effective energy is 
composed of a solute-solute term and a mean solvation term. The implicit force field model used 
to simulate the bilayer structures assumes that the mean solvation term is proportional to the 
SASA of the solute: 
 
where σi and Ai(r) are the atomic solvation parameter and the SASA of atom i, respectively. 
Integrating over the solvent coordinates is not a rigorous calculation and hence the atomic 
solvation parameters are required to fine-tune the mean solvation term. The atomic solvation 
parameters for different atom types were optimized in a trial-and-error approach by the Caflisch 
group to work in conjunction with the CHARMM force field.62, 63 
 3.3 Simulation of Aβ16-22 Oligomers and Fibril Structures 
In the initial stages of choosing the amyloid core to represent a portion of a fibril onto 
which an incoming strand incorporates, it was noticed that unrestrained simulations of β-sheets 
developed a slight, natural twist along the long axis of the β-sheet within a short amount of time, 
consistent with experimental observations of twisted fibril structures. To confirm that the 
simulation was indeed capturing the twisting nature of the peptide and not an incidental 
occurrence, large fibril-like structures were constructed and simulated to measure the amount 
and magnitude of any developing twist. The fibril structure consisted of four 100-mer bilayers 
grouped closely together. After a short 100 picosecond simulation to relax the structure, a 
twofold fibril developed with four β-sheets twisting together in each fibril (Figure 4). This 
confirmed that the simulation was in fact capturing the twisting effect of the Aβ16-22 fragment 
sequence. 
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Figure 4 Aβ16-22 Fibril Construction and Equilibration. The top and side views show the 
construction of the fibril. After a short equilibration, the fibril adopts a twisted conformation. 
 
 It was desired to retain the twisted nature of the Aβ peptide in the amyloid core to be 
simulated in order to create a model system that reflects the actual conformational features of the 
fibril. Additionally, the choice of a reasonably small system was preferred to minimize 
computation and increase possible sampling. Single layer and bilayer β-sheets fit these 
requirements, and variously sized sheets were examined for their stability and conformational 
differences. In test simulations, a single layer exhibited a very sharp twist along the long axis of 
the β-sheet, whereas a bilayer displayed a more gradual twist. The bilayer was ultimately chosen 
as the amyloid core as its gradual twist is likely a more representative feature to be found in the 
interior of an amyloid fibril. In addition, the presence of a neighboring sheet is believed to play a 
role in determining the templating kinetics.64  
To construct the bilayer structure to be used in the molecular dynamic simulations, a 
single strand is first generated with either the wildtype or one of the cyclohexane mutant 
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sequences using the molecular simulation program CHARMM. The backbone phi and psi angles 
are set to -140° and 135°, respectively, which correspond to those of a peptide in a representative 
anti-parallel β-strand conformation. The strand is then duplicated and translated to make two 
opposing sheets in a bilayer structure. Strands were separated by 5.6 angstroms on the long axis 
of the bilayer and every other strand was offset by 1.2 angstroms on the perpendicular axis so 
that the backbone hydrogen bonds would be aligned. The inter-sheet distance was set to 10 
angstroms. The geometry was based off of an NMR anti-parallel Aβ fibril structure from the 
RSCB Protein Data Bank. Unrestrained simulations of several differently sized bilayers indicated 
that a core of six strands in each sheet was stable over a period of one nanosecond (Figure 5). In 
order to minimize deviations from a representative amyloid core, therefore, a bilayer with 10-
mer sheets and restrained backbone hydrogen bonds was equilibrated long enough for the natural 
twist of the fibril to develop, and then the outer two peptides on each end of both sheets were 
deleted to leave a core with few perturbations. 
19 
 
 
Figure 5 Stability of Differently Sized Bilayers. Final conformations of variously sized 
bilayers after a 1 nanosecond MD simulation exhibit a varying degree of stability. A bilayer with 
six peptides in each β-sheet was determined to be the smallest, stable structure to be used as the 
amyloid core. 
 
Restraints were applied to the backbone hydrogen bonds of the bilayer structure that took 
effect when the distance between the heavy atoms in the hydrogen bond were farther than 3.5 
angstroms apart. The system was then equilibrated for 100 picoseconds to relax the structure and 
allow the natural fibril twist to develop (Figure 6). This relaxed bilayer structure was the 
template from which all in-register and mis-registered configurations were derived. To create a 
mis-registered configuration, the strands on each end of the fibril were first duplicated. The 
duplicate strands were then translated and rotated so that the backbone hydrogen bond acceptors 
and donors of the residue imitating first contact with the core superimposed those of the residue 
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on the original, in-register strand whose place it was taking. The end in-register strands were 
then deleted, leaving only the mis-registered strand.  
 
Figure 6 Twisting Effect of β-sheet After Equilibration. Restraints were applied to the 
backbone hydrogen bonds of the bilayer. After a short equilibration, the structure develops a 
dramatic twist. The test system on which this was performed is a bilayer, however, a single β-
sheet is shown here for clarity in visualizing the twist. 
 
The final step in creating each configuration was modifying the fully bound end strand to 
appear as though it has made only a single contact with the core. To create this effect, heavy 
atom restraints were applied to the amyloid core and to the residues on the end strands that were 
imitating the first contact. The system was then simulated at 1000 Kelvin for 100 picoseconds, 
resulting in the unrestrained portions of the end strands to dissociate from the core and assume a 
disordered conformation. For each configuration, fifty such preparative conformations were 
generated. Heavy atom restraints were again applied to the amyloid core as in the heating 
procedure to prevent disruptive interior events in detracting from the observation of transition 
dynamics of the end strands. Two sets of 50 nanosecond simulations were carried out at 300 
Kelvin using this setup, one with an additional heavy atom restraint on the residues of the end 
strands imitating the first contact with the core and one with no additional restraints added. Thus, 
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the restrained set enforces the end strands to remain in their assigned configuration, which 
facilitates focused sampling of hydrogen bonding dynamics of a given registry. The unrestrained 
end strands in the second set of simulations were able to explore other configurations or 
dissociate from the amyloid core completely. Overall, each configuration was simulated for a 
total of 500 nanoseconds, equivalent to1 µs of sampling with two independent peptides (Figure 
7). An illustrative initial conformation for each configuration and an explanation of the notation 
used to identify each can be found in Appendix A. 
 
Figure 7 Overview of Simulation Procedure 
 
 3.4 Results 
 3.4.1 Overview of Transition Data Matrix 
The complete 50 nanosecond trajectories for each configuration were analyzed for any 
conformational transitions as described in Chapter 2. The times that elapsed for each type of 
transition to occur follows a single exponential distribution as shown in Figure 8. This indicates 
that most transitions are indeed dominated by single barriers and are suitable for MSM 
description and the Gillespie algorithm.  
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Figure 8 Histogram Output of a Sample Conformational Transition. The horizontal axis is a 
range of times that elapsed before the transition occurred. The vertical axis is the number of 
times that transition was observed to occur. The sample transition shown here is the breaking of 
hydrogen bonds that results in the passage from a free chain length of 0 to 2 and the residues 
involved were a glutamate on the end strand and a lysine on the amyloid core. The transition 
times follow a single exponential distribution. 
 
The times for each type of transition were averaged and are listed in Appendix B. 
Overall, the mutant sequences experienced significantly slower hydrogen bond breakage 
transitions than those of the wildtype sequence (Table 2). There is not as strong a trend for bond 
formation transitions, as there is a slight increase in rates for transitions involved in in-register 
configurations and a mixed difference in rates for those in mis-registered configurations. In 
general, there does not seem to be an apparent dependence of the increase or decrease of 
transition times on the residue types involved. Some transitions that do not involve the mutant 
cyclohexane residue may exhibit a similar rate increase or decrease for all mutant sequences 
while other transitions that also involve a mutant cyclohexane residue may not have any 
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discernable pattern. The observed increase of experimental fibril growth rates for the mutant 
structures is therefore not likely explained solely by the specific set of interactions of paired side-
chains for a given sequence, but the collection of small effects propagated to all interactions by 
the introduction of a point mutation. 
 
Bond	  Breakage	  Transitions	  
	   Avg	  Time	  (ps)	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	  
	   WT	   CHA19	   CHA1920	   CHA20	  
In-­‐register	   1532	   1656	   28%	   1814	   55%	   1842	   48%	  
Mis-­‐register	   1705	   1668	   9%	   2038	   33%	   1861	   31%	  
 
Bond	  Formation	  Transitions	  
	   Avg	  Time	  (ps)	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	   Avg	  Time	  (ps)	   %	  Diff	  from	  WT	  
	   WT	   CHA19	   CHA1920	   CHA20	  
In-­‐register	   1046	   1307	   13%	   1279	   25%	   1297	   16%	  
Mis-­‐register	   984	   912	   -­‐6%	   797	   -­‐6%	   1059	   6%	  
 
Table 2 Average Times of Backbone Hydrogen Bond Formation and Breakage. 
Gradient fill colors are used to show the magnitude of the percent difference among mutant 
sequence transition rates in comparison to that of the wildtype sequence. Solid red refers to ≥ 
+100% difference, while solid green refers to ≤ -100% difference. 
 
Although there is not a discernable trend of the transition times in relation to the residue 
types involved, there is however a clear dependence on the free chain length. Hydrogen bond 
formation transition times increase as the free chain length increases, which is consistent with the 
idea that a longer disordered chain will be less dynamic due to viscous drag and slower to form 
hydrogen bonds on the amyloid core. It is not immediately clear if the breaking of hydrogen 
bonds is dependent on FCL. 
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Figure 9 Average Times of Backbone Hydrogen Bond Formation and Breakage Transitions 
as a Function of Free Chain Length. The average time for a transition to occur is plotted here 
in terms of the initial and final FCL. For bond breakage transitions, the final FCL is greater than 
the initial FCL, while the opposite is true for bond formation transitions. The average time to 
form hydrogen bonds increases with increasing FCL, whereas the average time to break 
hydrogen bonds decreases with increasing FCL. 
 
 3.4.2 Folding Probability 
The folding probability pfold of a protein structure recorded in an MD trajectory is the 
probability for the protein to fold before unfolding, starting from an intermediate conformation 
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between the native and unfolded state. This order parameter represents the kinetic distance of a 
structure from its native, folded state. A pfold value of 1 indicates all structures folded over the 
course of the trajectory, while a pfold value of 0 indicates all structures became unfolded. To 
calculate the pfold probability, folding and unfolding criteria must first be determined. To achieve 
this, a histogram plot was created of the probability of the two different amyloid core structures 
to have a number of formed backbone hydrogen bonds (Figure 10). The core structures are 
termed even and odd to refer to the number of hydrogen bond pairs available on the core peptide. 
 
 
Figure 10 Probability of Even and Odd Amyloid Cores Forming a Number of Backbone 
Hydrogen Bonds with the End Peptide. All trajectories were scanned for the number of 
hydrogen bonds formed between the end strand and the amyloid core. The occurrences for each 
possible number of hydrogen bonds for even and odd cores were recorded and divided by the 
total time. The resulting number is the probability of that number of hydrogen bonds to have 
occurred. The probabilities are plotted here for each number of hydrogen bonds. 
 
The data point slightly to the left of the peak bin will designate the most appropriate 
choice for the folding criteria. From the histogram data, a folding criterion of 4 and 5 backbone 
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hydrogen bonds for the odd and even core configurations, respectively, will likely describe the 
folded state of the peptide for the majority of conformations, and as such these parameters were 
used to define trajectories in which the end peptide became folded for the pfold analysis. End 
peptides were considered to become unfolded if their number of backbone hydrogen bonds 
dropped below one. To minimize noise in the data, the running average of the backbone 
hydrogen bonds for a particular configuration was computed over a time frame of 25 
picoseconds. In addition, any trajectories in which the end peptide already existed in the folded 
or unfolded state at the first frame were not included in the analysis, as pfold is the probability of 
the end peptide initially in an intermediately folded state moving to the folded conformation. The 
pfold values for in-register even and odd core configurations are plotted in Figure 11 and listed in 
Table 3. The notation on the horizontal axis used to define configurations is explained in 
Appendix A. 
 
Figure 11 Pfold of Wildtype and Mutant Structures After 50 Nanoseconds. The plotted pfold 
values correspond to in-register even and odd core configurations for the wildtype and mutant 
peptides. Lines between data points are plotted solely as a visual guide and do not signify any 
data evolution. 
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Table 3 Outcome and Pfold of End Peptides After 50 Nanoseconds 
	   	  
Configuration	  
	   Sequence	   e.2-­‐8	   e.4-­‐6	   e.6-­‐4	   e.8-­‐2	   o.3-­‐7	   o.5-­‐5	   o.7-­‐3	  
#	  Peptides	  Do	  Not	  Bind	  
WT	   70	   22	   21	   69	   45	   18	   56	  
CHA19	   68	   14	   20	   69	   43	   9	   53	  
CHA1920	   72	   21	   21	   64	   54	   6	   54	  
CHA20	   58	   18	   29	   69	   38	   18	   53	  
#	  Peptides	  Bind	  
WT	   18	   55	   54	   17	   29	   30	   26	  
CHA19	   17	   51	   53	   20	   30	   43	   26	  
CHA1920	   18	   60	   52	   20	   23	   51	   27	  
CHA20	   25	   54	   46	   18	   36	   38	   27	  
#	  Already	  Unfolded	  
WT	   10	   0	   5	   11	   3	   5	   4	  
CHA19	   13	   4	   2	   10	   9	   7	   8	  
CHA1920	   9	   1	   5	   15	   15	   5	   8	  
CHA20	   8	   3	   4	   10	   6	   3	   3	  
#	  Already	  Bound	  
WT	   2	   23	   20	   3	   23	   47	   14	  
CHA19	   2	   31	   25	   1	   18	   41	   13	  
CHA1920	   7	   25	   21	   3	   18	   41	   15	  
CHA20	   4	   34	   22	   3	   21	   35	   18	  
Pfold	  
WT	   0.205	   0.714	   0.720	   0.198	   0.392	   0.625	   0.317	  
CHA19	   0.200	   0.785	   0.726	   0.225	   0.411	   0.827	   0.329	  
CHA1920	   0.200	   0.741	   0.712	   0.238	   0.299	   0.895	   0.333	  
CHA20	   0.301	   0.750	   0.613	   0.207	   0.486	   0.679	   0.338	  
 
The kinetic theory has predicted that the transition state of templating occurs early, 
around when the peptide forms its first hydrogen bond pair of a native registry. The MD 
simulations here are consistent with this prediction, showing that all initial configurations with 
one registered hydrogen bond pair have a pfold value in the region of 0.5, ranging from 0.2 to 0.9. 
Considering that the pfold values are exponentially related to the location of the structure on the 
energy landscape, the observed values exhibiting the same magnitude as 0.5 suggest an initial 
structure close to both binding or unbinding, which is consistent with the predicted outcome of a 
peptide making a single contact with the amyloid core. The simulation also captures interesting 
heterogeneity in the pfold values of different configurations. The in-register peptides whose initial 
contact is more lateral with respect to the amyloid core exhibit a lower probability of folding 
since they have a longer initial free chain length, which causes the end peptide to be more 
dynamic and more likely to unfold. If the initial contact is more central between the end and core 
strands, the end strand is more stable and the pfold value is logically larger. 
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 3.4.3 Estimating Fibril Growth Through the Markov State Model 
 3.4.3.1 Algorithm Details 
The averaged transition data was used to provide the kinetic rates between states in a 
MSM.  The Gillespie algorithm was then used to generate a trajectory of a peptide interacting 
with an amyloid core given that at least a single contact is already formed. The same states as 
specified in the MD simulations are involved in the MSM given by free chain length and the 
interacting residues between the end and core peptides at the site adjacent to the free chain, 
which will be termed the residue pair. At each iteration of the algorithm, the current state of the 
peptide is calculated and then the possible states to which the peptide can transition are 
determined. Next, two random numbers are generated which determine which state will occur 
and how much time elapses before the peptide assumes that state, as described in Chapter 2. The 
algorithm continues until a desired state is reached. 
 3.4.3.2 Using Experimental and MSM Data to Calculate Theoretical Rates 
To calculate the fibril growth rate as depicted by the Markov state model, equation 1 is 
adapted to 
 
The diffusion time is expected to be inversely proportional to the concentration of the 
monomeric peptide in solution, c. The fitting parameter a is also introduced here and represents 
the probability of a random collision leading to the formation of the first hydrogen bond pair. At 
equilibrium, the rate of fibril growth is equal to the rate of fibril dissolution. The rate of fibril 
dissolution is equal to the quantity 1/toff, where toff is the average residence time of a peptide fully 
bound to the amyloid core in its optimal configuration before it dissociates. Since the equilibrium 
concentration of the monomeric peptide, CR, is known from the experimental study, the 
experimental constant a can be solved for: 
 
Once a is known, the fibril growth rate and diffusion time can be calculated from equation 9. 
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From the fully bound state in each configuration, 3000 MSM simulations were performed 
to calculate the average residence time, toff. The times are plotted in Figure 12 and Appendix A 
provides an explanation of the notation used on the horizontal axis to describe the configurations 
with fully bound end peptides. There is a clear distinction in residence times among the different 
sequences, but there is not a general trend for a given sequence to have a longer or shorter 
residence time across all configurations.  
 
 
Figure 12 Average Residence Times as Determined by Markov State Model for 
Configurations Previously Simulated with Molecular Dynamics. The configurations that 
were simulated with MD were simulated with the MSM. The average residence time for the end 
peptide as calculated from 3000 MSM simulations are plotted here for each configuration. 
 
In addition, 10,000 simulations were performed starting from a random configuration 
making a single contact with the amyloid core. The success rate of peptides becoming fully 
bound in the optimal, in-register configuration was recorded and this quantity is equivalent to 
P+/(2L – 1). The average time of mis-registered peptides to dissociate was calculated as the value 
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for twait. With all the unknowns of equation 10 determined, the diffusion time for each sequence 
was then calculated. The calculated values for each sequence are listed in Table 4. 
 
Table 4 Calculated Values for Determining the Diffusion Time at Fibrillization 
Equilibrium 
Sequence P+/(2L – 1) toff (ps) twait (ps) tdiff (ps) 
Wildtype 0.0181 22213 994 -592 
Cha 19 0.0181 34984 1268 -633 
Cha 20 0.0193 35517 1578 -894 
Cha 19,20 0.0190 32857 1809 -1183 
 
Noticeably, the calculated diffusion times are negative for each sequence, which suggests 
that one of the values derived from the Markov state model is incorrect. An assumption of the 
MSM is that once a peptide breaks its last contact with the core, it dissociates and contributes to 
the monomeric population in solution. However, another plausible scenario is that the peptide 
actually persists in a nonspecifically bound state for an amount of time comparable to the 
templating time scales before it completely dissociates or reforms hydrogen bonds. If true, the 
current MSM model will underestimate toff by ignoring the critical nonspecifically bound states. 
To check if such events have significant occurrence, 100 nanosecond MD simulations of fully 
bound, in-register configurations were performed with no restraints placed on the end peptide, 
allowing it the ability to dissociate. The resulting trajectories were analyzed to find the register 
state of the unrestrained peptides.  
The register state of the end peptides are defined in terms of the β-strand orientation of 
the peptide, either parallel or anti-parallel; the shift of the peptide, which refers to the degree of 
displacement in relation to the core with 0 corresponding to an in-register strand and +/- N 
corresponding to a mis-registered strand shifted +/- N hydrogen backbone pairs to one side; and 
whether there is an even or odd number of hydrogen bond pairs available for binding on the 
amyloid core and the end strand (see Appendix A for further explanation of register state 
notation).  
If the strand was involved in making backbone hydrogen bond contacts that did not 
unanimously agree with one register state, it was said to exist in a nonspecific state. In addition, 
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if no backbone hydrogen bond contacts were formed, but the strand was still proximal to the 
bilayer core, the register state was also classified as nonspecific. Finally, if the strand was not 
proximal to the bilayer core, it was said to exist in a dissociated state. The register states of the 
end peptides were computed as a function of time, a sample plot of which can be seen in Figure 
13. Table 5 lists the number of end peptides that changed their register state or remained in their 
original configuration at the end of a 100 nanosecond simulation. Fifty trajectories were 
generated for all four possible in-register configurations to offer 100 unrestrained end peptides 
capable of sampling different register states. All configurations exhibited some peptides that 
changed their register state by the end of the 100 nanosecond period. Clearly, changes from one 
register state to another through a transitional, nonspecifically bound state for the end peptides 
are a common event and will need to be accommodated in the Markov state model. 
 
 
Figure 13 Sample Plot for the Register State of an Unrestrained End Peptide as a Function 
of Time. The register state of the end peptides were tracked along the course of the MD 
simulations. At each frame in the trajectory (marked on the horizontal axis), the peptide was 
assigned to have one of the register states listed on the vertical axis. The sample plot shown here 
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indicates that this particular peptide stayed in its initial anti-parallel|0|odd|odd register state for 
the first half of the simulation before assuming a nonspecifically bound register state for a 
significant amount of time and then finally settling on the parallel|1|odd|odd register state. For 
Aβ16-22, there are a total of 52 possible register states, however, the vertical axis only lists the 
register states the peptide experienced in the sample trajectory for clarity. 
 
 
Table 5 Outcome of Unrestrained End Peptides After 100 Nanosecond Simulation  
 Number of End Peptides 
Configuration Remained In Original Register State Changed Register State 
e.2-8 44 56 
o.3-7 26 74 
e.3-3 91 9 
o.4-4 30 70 
 
To check the accuracy of the toff values used in the diffusion time calculation, the 
Markov state model residence times for the wildtype sequence were compared with the residence 
times as observed in the MD simulations (Figure 14). Starting from a fully bound state, the 
residence time is measured as the amount of time that elapses before the end peptide breaks its 
last backbone hydrogen bond pair or assumes the previously defined “non-specific” register state 
as observed in the Markov state model or the MD simulations, respectively. The residence times 
for the Markov state model were averaged from 3000 unbinding events for each configuration 
and thus can be considered a precise number for the model. The labels above the wildtype MD 
simulation data points indicate the number of times the end peptide was observed to assume the 
non-specific register state given that it started in the configuration specified on the horizontal 
axis. Several configurations experienced few end peptide unbinding events, and so the 
corresponding residence times must be considered tentative values. The MD simulation 
residence times must also be taken with reservations because trajectories in which the end 
peptide did not change its register state were not accounted for in the residence times. Therefore, 
the MD residence times are likely less than the actual time that end peptides stay bound to the 
core, which may be a contributing factor to the negative diffusion times that were calculated. 
Despite the unreliability of the MD data, the plotted comparison shows that the Markov state 
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model is able to capture the general trend of the MD simulation residence times. This 
observation further supports the notion that the MSM as implemented is correct, although 
incomplete since the critical nonspecifically bound states have been ignored. 
 
Figure 14 Average Residence Time Comparison Between the Markov State Model and MD 
Simulations for the Wildtype Sequence. The plot shown here compares the residence times of 
the wildtype end peptide as observed in the MD simulations and MSM. The labels above the MD 
simulation data points indicate the number of times the end peptide was observed to assume the 
non-specific register state given that it started in the configuration specified on the horizontal 
axis. 
 
 3.5 Discussion and Future Work 
Conformational transition data from MD simulations of Aβ16-22 wildtype and mutant 
systems in terms of free chain length and the interacting residues were not found to be identical 
among the different sequences. When the transition data was used in a Markov state model to 
simulate a fully bound peptide dissociating from an amyloid core structure, the resulting 
residence times vary depending on from which sequence the transition data were collected and 
also the residence times from the model reflect those determined from the MD simulations. This 
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indicates that the order parameters that define the conformational transitions and their 
implementation in the model are capable of capturing kinetic differences that are sequence 
dependent. However, when pfold, toff, and twait numbers were determined from the model and used 
in conjunction with experimental data to determine the fibril growth rate, the calculation 
incorrectly yields negative values for the peptide diffusion time. Investigation revealed that the 
model might be estimating the residence time to be too short. Also, the model assumes that once 
a peptide breaks its last backbone hydrogen bond pair, the peptide dissociates free of the amyloid 
core and becomes part of the monomeric population in solution, whereas a more probable 
scenario is one where the peptide becomes nonspecifically associated with the amyloid core once 
it breaks its last contact. These nonspecifically bound peptides then have the opportunity of 
dissociating or reincorporating into the amyloid core, not necessarily in its initial configuration. 
Future work on the model, therefore, should focus on adding the possibility of peptides assuming 
a nonspecific state. In combination with the experimental data, the revised kinetics of the model 
may then be able to provide an accurate estimate of amyloid fibril growth.
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Appendix A - Configuration Figures and Notation 
 A.1 Notation for Configurations with a Single Initial Contact 
Due to the many in-register and mis-registered conformations capable of being formed by 
the Aβ16-22 fragment model system, a three character notation system was devised to identify 
each configuration that was simulated. The first character describes the amyloid core onto which 
the end peptide joins. Since the model peptide has 7 residues, the amyloid core will either have 
an odd or an even number of backbone hydrogen bond pairs available for bonding with the end 
peptide, depending on the orientation of the most exterior peptide in the core. Hence, the first 
character is either “e” or “o” for an even or an odd number of available backbone hydrogen bond 
pairs, respectively. As such, the terms even core or odd core will be used as an abbreviated 
phrase to describe the number of available backbone hydrogen bond pairs on the amyloid core 
(Figure 15). 
 
Figure 15 Bonding Differences of the Amyloid Core. The two types of amyloid cores are 
shown here (odd or even) and the number of backbone hydrogen bond pairs is indicated by the 
bold red numbers. 
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The next two characters identify which residue pair was restrained during the heating 
simulation to give the end peptide a conformation that mimics an incoming strand having just 
formed a single pair of backbone hydrogen bonds. The second character refers to the strand 
residue ID and the third character refers to the core residue ID in pdb format. The first residue ID 
of the model system refers to an acetyl group capping residue that imitates a peptide bond 
connecting the fragment to the omitted residues. Residue IDs 2-8 correspond to the fragment 
residues 16-22. See Figure A.2 for an example of an in-register configuration name. 
 
 
Figure 16 Schematic of Configuration e.2-8. The notation for the configuration shown here is 
e.2-8. The letter “e” indicates that the end strand is contacting an even core, an amyloid core with 
an even number of backbone hydrogen bond pairs. The numeric pair “2-8” indicates that residue 
number 2 on the end strand and residue number 8 on the core are restrained to maintain their 
hydrogen bonds. 
 
 A.2 Register State Notation 
The notation used to describe the register states an incoming peptide of any sequence can 
assume involves four parameters. The first simply denotes the β-strand orientation: parallel or 
anti-parallel. The second parameter is termed the peptide’s “shift” and relates to what degree the 
strand is mis-aligned on the amyloid core. A shift of zero corresponds to an in-register strand, 
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while positive or negative integers indicate a strand mis-registered in the direction of its C-
terminus or N-terminus, respectively. The third parameter specifies whether the residue numbers 
of the end strand making backbone hydrogen bonds with the core are even or odd. Likewise, the 
fourth parameter is even or odd based on the residue numbers of the core strand that form 
backbone hydrogen bonds with the end strand.  
This notation system can describe any register state for a particular peptide. The 
difference between the notation outlined here and the one detailed in the previous section is that 
the initial single contact between the end strand and amyloid core is not specified in this system. 
In addition, the notation described earlier is specific to the Aβ16-22 peptide; a different system 
would need to be created to describe other sequences. As an example to delineate the two 
different systems, the notation “anti-parallel|0|even|even” describes the in-register end peptide 
shown in Figure A.2. That same peptide is also capable of being classified as configuration e.2-8, 
e.4-6, e.6-4, or e.8-2, depending on the initial contact with which it was set up.  
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 A.3 Configuration Figures 
The following figures depict a representative structure of all the configurations that were 
simulated as described in section 3.3 at the end of the 100 picosecond heating simulation. The 
dashed blue bonds represent backbone hydrogen bonds. The heated simulation produces a 
structure that mimics an incoming peptide making a single contact with the amyloid core.  
A.3.1 In-register, Anti-parallel Configurations 
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A.3.2 Mis-registered, Anti-parallel Configurations 
 
 
 
40 
 
41 
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